These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1362267)

  • 61. The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.
    Engleman EA; Rodd ZA; Bell RL; Murphy JM
    CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):454-67. PubMed ID: 19128203
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 5-HT3 receptor antagonists attenuate cocaine-induced locomotion in mice.
    Reith ME
    Eur J Pharmacol; 1990 Sep; 186(2-3):327-30. PubMed ID: 2289534
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.
    Langlois A; Pascaud X; Junien JL; Dahl SG; Rivière PJ
    Eur J Pharmacol; 1996 Dec; 318(1):141-4. PubMed ID: 9007525
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
    Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
    Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serotonin receptor subtypes: implications for psychopharmacology.
    Cowen PJ
    Br J Psychiatry Suppl; 1991 Sep; (12):7-14. PubMed ID: 1840764
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Anxiolytic-like effect of way-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience.
    Canto-de-Souza A; Luiz Nunes-de-Souza R; Rodgers RJ
    Brain Res; 2002 Feb; 928(1-2):50-9. PubMed ID: 11844471
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characterization of 5-HT3 and 'atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro.
    Eglen RM; Swank SR; Walsh LK; Whiting RL
    Br J Pharmacol; 1990 Nov; 101(3):513-20. PubMed ID: 2076474
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preclinical pharmacology of FG5893: a potential anxiolytic drug with high affinity for both 5-HT1A and 5-HT2A receptors.
    Albinsson A; Björk A; Svartengren J; Klint T; Andersson G
    Eur J Pharmacol; 1994 Aug; 261(3):285-94. PubMed ID: 7813550
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants.
    Levy AD; Van de Kar LD
    Life Sci; 1992; 51(2):83-94. PubMed ID: 1352027
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
    Barnes JM; Barnes NM
    Biochem Pharmacol; 1993 May; 45(10):2155-8. PubMed ID: 8390263
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Distribution and characterisation of the [3H](S)-zacopride labelled 5-HT3 receptor in pig forebrain.
    Fletcher S; Barnes NM
    Brain Res; 1996 Aug; 729(2):281-4. PubMed ID: 8877001
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of 5-HT3 receptors in drug dependence.
    Grant KA
    Drug Alcohol Depend; 1995 May; 38(2):155-71. PubMed ID: 7671767
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test.
    Redrobe JP; Bourin M
    Eur J Pharmacol; 1997 May; 325(2-3):129-35. PubMed ID: 9163559
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Pharmacological review of tropisetron].
    Yokoyama T
    Nihon Yakurigaku Zasshi; 1999 Oct; 114(4):219-26. PubMed ID: 10584235
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Profile of action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset.
    Costall B; Domeney AM; Farre AJ; Kelly ME; Martinez L; Naylor RJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):90-8. PubMed ID: 1352556
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of 5-HT3 receptor antagonists on 5-HT and nicotinic depolarizations in guinea-pig submucosal neurones.
    Vanner S; Surprenant A
    Br J Pharmacol; 1990 Apr; 99(4):840-4. PubMed ID: 2141798
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse.
    Eglen RM; Lee CH; Khabbaz M; Fontana DJ; Daniels S; Kilfoil T; Wong EH
    Neuropharmacology; 1994 Feb; 33(2):227-34. PubMed ID: 8035908
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of (S)-des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a selective high-affinity radioligand for 5-hydroxytryptamine3 receptors.
    Hewlett WA; Trivedi BL; Zhang ZJ; de Paulis T; Schmidt DE; Lovinger DM; Ansari MS; Ebert MH
    J Pharmacol Exp Ther; 1999 Jan; 288(1):221-31. PubMed ID: 9862774
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 5-HT3-like receptors in the rat medial prefrontal cortex: an electrophysiological study.
    Ashby CR; Minabe Y; Edwards E; Wang RY
    Brain Res; 1991 Jun; 550(2):181-91. PubMed ID: 1679370
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T; Yoshida N; Oka M
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.